Conference Intelligence Dossier: EASD Annual Meeting 2009
The numbers are staggering: More than 200 million people around the world now suffer from diabetes and its major complications. According to the World Health Organization, that figure is expected to surpass 366 million by 2030—even if obesity rates remain constant.i
The race to find innovative new treatments, pharmaceutical advances, and therapies is on. Recently, at the annual European Association for the Study of Diabetes (EASD) conference, the diabetes research community gathered in Vienna to discuss the latest findings.
The conference, held from September 29 to October 2, heard scientists, researchers and, key thinkers report on everything from incretin-based therapies and positive outcomes in the LEAD studies showing liraglutide usage in obese type 2 diabetes patients, to updates for a host of other GLP-1 analogues. In addition, several breakthroughs in new therapeutic agents like SGLT2 inhibitors and DPP-IV Inhibitors -considered an emerging option in hyperglycaemia management - took centre stage.
FirstWord’s Conference Intelligence Dossier: EASD Annual Meeting 2009 offers you a window into the symposium attended by more than 17,000 international endocrinologists, diabetologists, scientists, and researchers. A platform for showcasing numerous research efforts and treatment discoveries, the 45th annual EASD conference expanded the knowledge base through discussions of therapeutic breakthroughs, developments, and drug profiles.
Key insights from the conference
Over 90 pages, FirstWord’s conference dossier efficiently gathers the relevant information, from analyses of headlining abstracts delivered by world-renowned researchers to insightful interviews with key industry voices. The dossier provides an accurate, concise overview of all aspects of the conference, including posters, biographies, and research highlights focused on diabetes and obesity pathogenesis. In addition, FirstWord’s Conference Intelligence Dossier: EASD Annual Meeting 2009 includes a unique counterpoint segment on the conference’s social media activities, which outlines ways in which health care professionals and diabetes specialists might use new technology to engage in transparent, reciprocal, and relevant communication.
FirstWord’s conference dossier offers:
Social media sites analysed:
Twitter
Facebook
The race to find innovative new treatments, pharmaceutical advances, and therapies is on. Recently, at the annual European Association for the Study of Diabetes (EASD) conference, the diabetes research community gathered in Vienna to discuss the latest findings.
The conference, held from September 29 to October 2, heard scientists, researchers and, key thinkers report on everything from incretin-based therapies and positive outcomes in the LEAD studies showing liraglutide usage in obese type 2 diabetes patients, to updates for a host of other GLP-1 analogues. In addition, several breakthroughs in new therapeutic agents like SGLT2 inhibitors and DPP-IV Inhibitors -considered an emerging option in hyperglycaemia management - took centre stage.
FirstWord’s Conference Intelligence Dossier: EASD Annual Meeting 2009 offers you a window into the symposium attended by more than 17,000 international endocrinologists, diabetologists, scientists, and researchers. A platform for showcasing numerous research efforts and treatment discoveries, the 45th annual EASD conference expanded the knowledge base through discussions of therapeutic breakthroughs, developments, and drug profiles.
Key insights from the conference
Over 90 pages, FirstWord’s conference dossier efficiently gathers the relevant information, from analyses of headlining abstracts delivered by world-renowned researchers to insightful interviews with key industry voices. The dossier provides an accurate, concise overview of all aspects of the conference, including posters, biographies, and research highlights focused on diabetes and obesity pathogenesis. In addition, FirstWord’s Conference Intelligence Dossier: EASD Annual Meeting 2009 includes a unique counterpoint segment on the conference’s social media activities, which outlines ways in which health care professionals and diabetes specialists might use new technology to engage in transparent, reciprocal, and relevant communication.
FirstWord’s conference dossier offers:
- Synopses of key abstracts, including all relevant drug posters
- Wide-ranging analysis of new developments and research efforts focusing on emerging GLP-1 analogues, DPP-IV inhibitors, and SGLT2 therapy classes, grouped by field and including:
- Liraglutide (Victoza) and results from the LEAD studies
- Exenatide (Byetta) and outcomes from the DURATION-2 study highlighting the benefits of once-weekly use of exenatide over other therapies
- Updates on regulatory delays affecting Takeda’s DPP-4 inhibitor, alogliptin
- Analysis of saxagliptin (Onglyza) , the new DPP-IV inhibitor from Bristol-Myers Squibb and AstraZeneca
- Promising results for colesevelam, a bile acid sequestrant
- A detailed overview of successes and misfires of social media use, as well as potential uses
- Interviews with key voices, as well as key presenter biographies
Social media sites analysed:
EXECUTIVE SUMMARY
CLINICAL DATA
Glucagon-like peptide 1 (GLP-1) analogues
Liraglutide
LEAD 6 extension – switching from exenatide to liraglutide provides benefits
Two-year LEAD-2 study data
Liraglutide shows superiority to glimepiride in controlling β-cell function
Liraglutide improves prediabetes and glycaemic levels in obese patients
Exenatide
Exenatide improves β-cell response
Exenatide treatment in type 2 diabetes shows no increased relative risk of pancreatitis
Albiglutide
Albiglutide improves glycaemic control: time-course analysis
Taspoglutide
Lixisenatide
Post-meal pharmacodynamic profile of AVE0010
LY2189265
The EGO study analysis: LY2189265 is effective in overweight/obese patients with type 2 diabetes
Dipeptidyl peptidase 4 (DPP-4) inhibitors
Alogliptin
Saxagliptin
Saxagliptin plus metformin or glibenclamide significantly improves glycaemic control
Saxagliptin plus metformin provides long-term benefits in type 2 diabetes patients
Vildagliptin
Vildagliptin therapy shows no evidence of increasing pancreatitis risk
Sitagliptin
Sitagliptin shows efficacy for up to 2 years in type 2 diabetes, either alone or as add-on therapy
Sitagliptin plus metformin shows promise for glycaemic control, and reduced gastrointestinal side effects
Sitagliptin improves glucose tolerance in type 2 diabetes patients
Novel type 2 diabetes therapies
Dapagliflozin
Safety and efficacy of dapagliflozin add-on to metformin in type 2 diabetes patients
Safety and efficacy of dapagliflozin in patients poorly controlled with insulin plus metformin and/or thiazolidinediones
Colesevelam HCl
Glucose-lowering effects of colesevelam HCl
INCB13739
INCB13739 demonstrates improvements in HbA1c and low-density lipoprotein cholesterol in patients with type 2 diabetes
VI-0521
Glycaemic and weight loss effects of VI-0521
DIABETES AND CANCER
FIRSTWORD INTERVIEW WITH SELECTED KEY OPINION LEADERS
SOCIAL MEDIA ACTIVITY AT EASD 2009
Quantitative and qualitative activity analyses
Twitter: status updating
Facebook: social networking
Shared content: video, image and document services
Professional networking
Social media spotlights: activity analysis at EASD by constituency
Key opinion leaders
Pharmaceutical industry
Professional societies
Trending topics within social media at EASD
Issues: debate, interaction, conversation and comment
Events: planned, spontaneous, formal and casual
Beyond the congress centre
Blog coverage of EASD
Counterpoints: social media representations of EASD
BIOGRAPHIES OF KEY PRESENTERS
CLINICAL DATA
Glucagon-like peptide 1 (GLP-1) analogues
Liraglutide
LEAD 6 extension – switching from exenatide to liraglutide provides benefits
Two-year LEAD-2 study data
Liraglutide shows superiority to glimepiride in controlling β-cell function
Liraglutide improves prediabetes and glycaemic levels in obese patients
Exenatide
Exenatide improves β-cell response
Exenatide treatment in type 2 diabetes shows no increased relative risk of pancreatitis
Albiglutide
Albiglutide improves glycaemic control: time-course analysis
Taspoglutide
Lixisenatide
Post-meal pharmacodynamic profile of AVE0010
LY2189265
The EGO study analysis: LY2189265 is effective in overweight/obese patients with type 2 diabetes
Dipeptidyl peptidase 4 (DPP-4) inhibitors
Alogliptin
Saxagliptin
Saxagliptin plus metformin or glibenclamide significantly improves glycaemic control
Saxagliptin plus metformin provides long-term benefits in type 2 diabetes patients
Vildagliptin
Vildagliptin therapy shows no evidence of increasing pancreatitis risk
Sitagliptin
Sitagliptin shows efficacy for up to 2 years in type 2 diabetes, either alone or as add-on therapy
Sitagliptin plus metformin shows promise for glycaemic control, and reduced gastrointestinal side effects
Sitagliptin improves glucose tolerance in type 2 diabetes patients
Novel type 2 diabetes therapies
Dapagliflozin
Safety and efficacy of dapagliflozin add-on to metformin in type 2 diabetes patients
Safety and efficacy of dapagliflozin in patients poorly controlled with insulin plus metformin and/or thiazolidinediones
Colesevelam HCl
Glucose-lowering effects of colesevelam HCl
INCB13739
INCB13739 demonstrates improvements in HbA1c and low-density lipoprotein cholesterol in patients with type 2 diabetes
VI-0521
Glycaemic and weight loss effects of VI-0521
DIABETES AND CANCER
FIRSTWORD INTERVIEW WITH SELECTED KEY OPINION LEADERS
SOCIAL MEDIA ACTIVITY AT EASD 2009
Quantitative and qualitative activity analyses
Twitter: status updating
Facebook: social networking
Shared content: video, image and document services
Professional networking
Social media spotlights: activity analysis at EASD by constituency
Key opinion leaders
Pharmaceutical industry
Professional societies
Trending topics within social media at EASD
Issues: debate, interaction, conversation and comment
Events: planned, spontaneous, formal and casual
Beyond the congress centre
Blog coverage of EASD
Counterpoints: social media representations of EASD
BIOGRAPHIES OF KEY PRESENTERS
